New research on tirzepatide, the drug behind Zepbound and Mounjaro, suggests it could significantly lower the risk of major cardiovascular event.
Popular Weight-Loss Drug May Cut Heart Attack Risk by 54%, New Studies Find
Leila Sheridan·Inc. Magazine··1 min read
I
Continue reading on Inc. Magazine
This article was sourced from Inc. Magazine's RSS feed. Visit the original for the complete story.